

**Wright Medical Group N.V.**  
**Supplemental Net Sales Information**  
(unaudited)

**Three months ended September 30, 2018 net sales growth/(decline)**

<b>Product line</b>	<b><u>U.S. as reported</u></b>	<b><u>Int'l constant currency</u></b>	<b><u>Int'l as reported</u></b>	<b><u>Global constant currency</u></b>	<b><u>Global as reported</u></b>
Lower extremities	12%	(1%)	(3%)	9%	9%
Upper extremities	19%	23%	21%	20%	20%
Biologics	11%	29%	26%	15%	14%
Sports med & other	(2%)	(14%)	(14%)	(9%)	(10%)
<b>Total net sales</b>	<b>15%</b>	<b>13%</b>	<b>11%</b>	<b>14%</b>	<b>14%</b>

**Nine months ended September 30, 2018 net sales growth/(decline)**

<b>Product line</b>	<b><u>U.S. as reported</u></b>	<b><u>Int'l constant currency</u></b>	<b><u>Int'l as reported</u></b>	<b><u>Global constant currency</u></b>	<b><u>Global as reported</u></b>
Lower extremities	8%	1%	5%	6%	7%
Upper extremities	21%	20%	27%	21%	22%
Biologics	4%	18%	19%	7%	7%
Sports med & other	(1%)	(25%)	(20%)	(16%)	(13%)
<b>Total net sales</b>	<b>13%</b>	<b>10%</b>	<b>15%</b>	<b>12%</b>	<b>13%</b>

**Wright Medical Group N.V.**

**Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Loss from Continuing Operations Per Share**

(dollars in thousands, except per share data--unaudited)

	Three months ended		Nine months ended	
	September 30, 2018	September 24, 2017	September 30, 2018	September 24, 2017
<b>Net loss from continuing operations, as reported</b>	\$ (35,829)	\$ (34,122)	\$ (146,357)	\$ (91,789)
<b>Net loss from continuing operations per share, as reported</b>	\$ (0.32)	\$ (0.33)	\$ (1.35)	\$ (0.88)
Reconciling items:				
Non-cash interest expense on convertible notes <sup>1</sup>	12,326	11,494	36,613	33,743
Non-cash loss on extinguishment of debt <sup>2</sup>	—	—	39,935	—
Derivatives mark-to-market adjustments <sup>2</sup>	(230)	(199)	34,343	(4,163)
Transaction and transition costs	1,952	3,311	4,187	9,485
Foreign currency translation expense <sup>2</sup>	238	—	2,894	—
CVR mark-to-market adjustments <sup>2</sup>	3,363	4,485	(3,084)	6,721
Contingent consideration fair value adjustment <sup>2</sup>	327	133	1,106	309
Tax benefit related to realizability of net operating losses	—	(8,928)	—	(8,928)
U.S. tax provision (benefit) resulting from income from discontinued operations	2,216	—	(3,967)	—
Tax effect of reconciling items <sup>3</sup>	106	—	965	(70)
<b>Non-GAAP net loss from continuing operations, as adjusted</b>	\$ (15,531)	\$ (23,826)	\$ (33,365)	\$ (54,692)
Add back amortization of intangible assets	5,881	7,178	19,031	21,574
<b>Adjusted non-GAAP earnings</b>	\$ (9,650)	\$ (16,648)	\$ (14,334)	\$ (33,118)
Weighted-average basic shares outstanding	113,043	104,836	108,348	104,292
<b>Adjusted non-GAAP earnings per share</b>	\$ (0.09)	\$ (0.16)	\$ (0.13)	\$ (0.32)

<sup>1</sup> Impacting interest expense, net

<sup>2</sup> Impacting other expense, net

<sup>3</sup> Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations**  
(dollars in thousands--unaudited)

	Three months ended		Nine months ended	
	September 30, 2018	September 24, 2017	September 30, 2018	September 24, 2017
<b>Net loss from continuing operations</b>	\$ (35,829)	\$ (34,122)	\$ (146,357)	\$ (91,789)
Interest expense, net	19,753	18,978	60,243	55,512
Provision (benefit) from income taxes	3,040	(8,822)	(1,217)	(7,498)
Depreciation	14,604	15,000	42,986	42,124
Amortization	5,881	7,178	19,031	21,574
<b>Non-GAAP EBITDA</b>	<b>\$ 7,449</b>	<b>\$ (1,788)</b>	<b>\$ (25,314)</b>	<b>\$ 19,923</b>
Reconciling items impacting EBITDA:				
Non-cash share-based compensation expense	7,257	5,445	18,336	14,131
Other expense, net	3,902	5,457	75,649	6,875
Transaction and transition costs	1,952	3,311	4,187	9,485
<b>Non-GAAP adjusted EBITDA</b>	<b>\$ 20,560</b>	<b>\$ 12,425</b>	<b>\$ 72,858</b>	<b>\$ 50,414</b>
Net sales from continuing operations	194,106	170,503	598,043	527,387
<b>Non-GAAP adjusted EBITDA margin</b>	<b>10.6%</b>	<b>7.3%</b>	<b>12.2%</b>	<b>9.6%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations**  
(dollars in thousands--unaudited)

	Three months ended		Nine months ended	
	September 30, 2018	September 24, 2017	September 30, 2018	September 24, 2017
<b>Gross profit from continuing operations, as reported</b>	\$ 149,799	\$ 132,082	\$ 467,039	\$ 413,718
<b>Gross margins from continuing operations, as reported</b>	<b>77.2 %</b>	<b>77.5 %</b>	<b>78.1 %</b>	<b>78.4 %</b>
Reconciling items impacting gross profit:				
Transaction and transition costs	1,385	1,310	3,620	1,995
<b>Non-GAAP gross profit from continuing operations, as adjusted</b>	<b>\$ 151,184</b>	<b>\$ 133,392</b>	<b>\$ 470,659</b>	<b>\$ 415,713</b>
Net sales from continuing operations	194,106	170,503	598,043	527,387
<b>Non-GAAP adjusted gross margins from continuing operations</b>	<b>77.9%</b>	<b>78.2%</b>	<b>78.7%</b>	<b>78.8%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results**  
(dollars in thousands--unaudited)

	Three months ended		Nine months ended	
	September 30, 2018	September 24, 2017	September 30, 2018	September 24, 2017
<b>Net sales</b>	\$ 194,106	\$ 170,503	\$ 598,043	\$ 527,387
<b>Selling, general and administrative expense, as reported</b>	\$ 139,223	\$ 131,421	\$ 417,297	\$ 392,073
Selling, general and administrative expense as a percentage of net sales, as reported	71.7 %	77.1 %	69.8 %	74.3 %
Reconciling items impacting selling, general and administrative expense:				
Transaction and transition costs - selling, general and administrative	567	1,878	567	7,267
<b>Selling, general and administrative expense, as adjusted</b>	<b>\$ 138,656</b>	<b>\$ 129,543</b>	<b>\$ 416,730</b>	<b>\$ 384,806</b>
<b>Selling, general and administrative expense as a percentage of net sales, as adjusted</b>	<b>71.4%</b>	<b>76.0%</b>	<b>69.7%</b>	<b>73.0%</b>
<b>Research &amp; development expense, as reported</b>	\$ 13,829	\$ 11,992	\$ 42,393	\$ 36,971
Research & development expense as a percentage of net sales, as reported	7.1 %	7.0 %	7.1 %	7.0 %
Reconciling items impacting research & development expense:				
Transaction and transition costs - research & development	—	122	—	222
<b>Research &amp; development expense, as adjusted</b>	<b>\$ 13,829</b>	<b>\$ 11,870</b>	<b>\$ 42,393</b>	<b>\$ 36,749</b>
<b>Research &amp; development expense as a percentage of net sales, as adjusted</b>	<b>7.1%</b>	<b>7.0%</b>	<b>7.1%</b>	<b>7.0%</b>